Consensus Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.21 ^USD	+0.55%		-1.39%	-17.91%

Apr. 23	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	MT
Apr. 19	Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Fennec Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

5fe2f64fe17808e3a33.Ms7Rja-nYMq0QuNIIueYB6hDLXtIge8BD0Z8I0KmmII.Y_6I_fDzOLnlBqh6SbKtXdB2cgIPtKE2RiEteTPk1ehUtKPE68won-Avrg~4a17a95c0da2dce30f27dd7ed922b214

Analyst Recommendations on Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	Apr. 19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	Apr. 17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	Apr. 05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	Apr. 04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	Apr. 03	MT
HC Wainwright Adjusts Price Target on Fennec Pharmaceuticals to $17 From $18, Maintains Buy Rating	23-08-04	MT
Cantor Fitzgerald Adjusts Fennec Pharmaceuticals' Price Target to $16 From $12	23-04-06	MT
Wedbush Adjusts Fennec Pharmaceuticals Price Target to $16 From $17, Maintains Outperform Rating	23-03-30	MT
Wedbush Lowers Fennec Pharmaceuticals' Price Target to $17 From $19, Maintains Outperform Rating	23-01-25	MT
Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $12 From $9	22-11-22	MT
HC Wainwright Adjusts Fennec Pharmaceuticals' Price Target to $18 From $14, Keeps Buy Rating	22-10-20	MT
Maxim Adjusts Fennec Pharmaceuticals' Price Target to $15 from $10, Maintains Buy	22-09-29	MT
Wedbush Adjusts Fennec Pharmaceuticals Price Target to $19 From $11, Maintains Outperform Rating	22-09-26	MT
Capital One Starts Fennec Pharmaceuticals at Overweight With $11 Price Target	22-09-07	MT
Craig-Hallum Assumes Fennec Pharmaceuticals at Buy With $14 Price Target	22-08-08	MT
Wedbush Maintains Outperform, Raises Fennec Pharmaceuticals' TP to US$11	22-05-12	MT
Wedbush Lifts Price Target for Fennec Pharmaceuticals to $11 From $10, Maintains Outperform Rating	22-05-12	MT
Wedbush Maintains Outperform, US$10 TP on Fennec Pharmaceuticals After Q4, Pedmark Update	22-02-28	MT
Wedbush Lifts Price Target for Fennec Pharmaceuticals to $10 From $9, Maintains Outperform Rating	22-02-28	MT
Maxim Group Adjusts Price Target on Fennec Pharmaceuticals to $10 From $12, Keeps Buy Rating	21-12-01	MT
Craig-Hallum Adjusts Price Target on Fennec Pharmaceuticals to $14 From $19, Maintains Buy Rating	21-11-30	MT
Wedbush Maintains Outperform, US$9 TP, on Fennec Pharmaceuticals After Second Pedmark Delay	21-11-29	MT
Wedbush Adjusts Price Target on Fennec Pharmaceuticals to $9 From $12 on Pedmark Approval Delay; Outperform Rating Kept	21-11-29	MT
FENNEC PHARMACEUTICALS : Wedbush Lifts Price Target for Fennec Pharmaceuticals to $12 From $11, Maintains Outperform Rating	21-08-10	MT
FENNEC PHARMACEUTICALS : Craig-Hallum Starts Fennec Pharmaceuticals at Buy with $17 Price Target	21-04-21	MT